X-Square Capital’s Cardiff Oncology CRDF Stock Holding History

X-Square Capital’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-17,000	Closed	-$85K	–	98
2020 Q2	$85K	Buy	+17,000	New	+$34.8K	0.06%	88

Other funds holding CRDF

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

X-Square Capital's CRDF Position: Q3 2020 in Review

X-Square Capital sold out of Cardiff Oncology (CRDF) in Q3 2020, closing a stake of 17,000 shares — an estimated $85K sold.

X-Square Capital first reported a position in CRDF in Q2 2020 and held it in 1 quarter. The position peaked at $85K in Q2 2020. 67 funds tracked by Wall St. Rank hold CRDF as of Q3 2020.

X-Square Capital reported no remaining Cardiff Oncology position as of Q3 2020 after selling out during the quarter.
X-Square Capital sold 17,000 Cardiff Oncology shares in Q3 2020, an estimated $85K.
X-Square Capital first reported a position in Cardiff Oncology in Q2 2020 and held it in 1 quarter.
X-Square Capital's Cardiff Oncology position peaked at $85K in Q2 2020.
67 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2020.

Based on X-Square Capital's 13F filing for Q3 2020, filed 2 Nov 2020.